IN2PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
IN2PHARMA
Largest movements
- Cash +€203,282
up €203,282 (+156%), from €130,701 to €333,982
mainly Net result for the year (+€909,969) and Tax, wage and social debts (+€103,587)
- Receivables within one year -€73,793
down €73,793 (-6.1%), from €1.2m to €1.1m
of which Other amounts receivable: -€106,337
- Tax, wage and social debts +€103,587
up €103,587 (+56.3%), from €183,886 to €287,473
of which Remuneration and social security: +€79,227
- Trade debts +€88,108
up €88,108 (+99.8%), from €88,326 to €176,435
- Other debts -€52,529
down €52,529 (-5.3%), from €990,501 to €937,972
- Gross operating margin +€493,678
up €493,678 (+25.9%), from €1.9m to €2.4m
- Taxes +€309,690
up €309,690 (+7,911%), from €3,914 to €313,604
- Staff costs +€272,712
up €272,712 (+32.0%), from €851,814 to €1.1m
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,334,439 | €1,478,796 | +€144,357 | +10.8% |
| Fixed assets | 21/28 | €974 | €12,311 | +€11,337 | +1,164% |
| Tangible fixed assets | 22/27 | €974 | €12,311 | +€11,337 | +1,164% |
| Plant, machinery and equipment | 23 | - | €11,050 | +€11,050 | |
| Furniture and vehicles | 24 | €974 | €1,261 | +€287 | +29.5% |
| Current assets | 29/58 | €1,333,465 | €1,466,485 | +€133,020 | +10.0% |
| Amounts receivable after more than one year | 29 | €0 | - | = | |
| Other amounts receivable | 291 | €0 | - | = | |
| Amounts receivable within one year | 40/41 | €1,201,145 | €1,127,352 | -€73,793 | -6.1% |
| Trade receivables | 40 | €518,107 | €550,651 | +€32,544 | +6.3% |
| Other amounts receivable | 41 | €683,039 | €576,701 | -€106,337 | -15.6% |
| Cash at bank and in hand | 54/58 | €130,701 | €333,982 | +€203,282 | +156% |
| Deferred charges and accrued income | 490/1 | €1,619 | €5,150 | +€3,531 | +218% |
| Total equity and liabilities | 10/49 | €1,334,439 | €1,478,796 | +€144,357 | +10.8% |
| Equity | 10/15 | €69,300 | €69,300 | = | 0.0% |
| Contributions | 10/11 | €63,000 | €63,000 | = | 0.0% |
| Capital | 10 | €63,000 | €63,000 | = | 0.0% |
| Issued capital | 100 | €63,000 | €63,000 | = | 0.0% |
| Reserves | 13 | €6,300 | €6,300 | = | 0.0% |
| Non-distributable reserves | 130/1 | €6,300 | €6,300 | = | 0.0% |
| Legal reserve | 130 | €6,300 | €6,300 | = | 0.0% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €1,265,139 | €1,409,496 | +€144,357 | +11.4% |
| Amounts payable within one year | 42/48 | €1,262,713 | €1,401,879 | +€139,167 | +11.0% |
| Trade debts | 44 | €88,326 | €176,435 | +€88,108 | +99.8% |
| Suppliers | 440/4 | €88,326 | €176,435 | +€88,108 | +99.8% |
| Taxes, remuneration and social security | 45 | €183,886 | €287,473 | +€103,587 | +56.3% |
| Taxes | 450/3 | €25,081 | €49,441 | +€24,360 | +97.1% |
| Remuneration and social security | 454/9 | €158,804 | €238,032 | +€79,227 | +49.9% |
| Other amounts payable | 47/48 | €990,501 | €937,972 | -€52,529 | -5.3% |
| Accrued charges and deferred income | 492/3 | €2,427 | €7,617 | +€5,190 | +214% |
| Remuneration, social security and pensions | 62 | €851,814 | €1,124,526 | +€272,712 | +32.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €614 | €1,064 | +€450 | +73.3% |
| Other operating charges | 640/8 | €61,050 | €49,192 | -€11,858 | -19.4% |
| Non-recurring operating charges | 66A | €4,987 | €0 | -€4,987 | -100% |
| Gross operating margin | 9900 | €1,906,025 | €2,399,703 | +€493,678 | +25.9% |
| Operating profit (loss) | 9901 | €987,561 | €1,224,922 | +€237,361 | +24.0% |
| Financial income | 75/76B | €7,305 | €0 | -€7,305 | -100% |
| Recurring financial income | 75 | €7,305 | €0 | -€7,305 | -100% |
| Financial charges | 65/66B | €6,063 | €1,349 | -€4,714 | -77.7% |
| Recurring financial charges | 65 | €6,063 | €1,349 | -€4,714 | -77.7% |
| Profit (loss) for the period before taxes | 9903 | €988,802 | €1,223,573 | +€234,770 | +23.7% |
| Income taxes | 67/77 | €3,914 | €313,604 | +€309,690 | +7,911% |
| Profit (loss) for the period | 9904 | €984,888 | €909,969 | -€74,919 | -7.6% |
| Profit (loss) for the period to be appropriated | 9905 | €984,888 | €909,969 | -€74,919 | -7.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 14 October 2026 via checked.be.